首页> 外文期刊>Thoracic cancer. >Expression of tumor necrosis factor receptor 2 in human non‐small cell lung cancer and its role as a potential prognostic biomarker
【24h】

Expression of tumor necrosis factor receptor 2 in human non‐small cell lung cancer and its role as a potential prognostic biomarker

机译:肿瘤坏死因子受体2在人非小细胞肺癌中的表达及其作为潜在预后生物标志物的作用

获取原文
           

摘要

Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in three NSCLC cell lines (A549, H1299, H1975) and normal lung epithelial cells (BEAS-2B). TNFR2 was evaluated in 71 tumor tissues and 25 adjacent normal lung tissues by immunohistochemistry and analyzed with respect to clinical parameters. The messenger RNA and protein levels of TNFR2 were significantly higher in A549, H1299, and H1975 cells than in BEAS-2B cells (P??0.05) and differed significantly between NSCLC tissues and adjacent normal lung tissues by immunohistochemistry (P??0.0001). TNFR2 is a independent prognostic factor in NSCLC. There have significantly differences in overall survival (OS) (P?=?0.006) and disease-free survival (DFS) (P?=?0.000) of NSCLC patients between TNFR2 low expression groups and TNFR2 high expression group. TNFR2 is expressed in human NSCLC tissues and cell lines and is related to poor prognosis. TNFR2 may represent a new auxiliary index for patients with NSCLC. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:肿瘤坏死因子受体2(TNFR2)促进肿瘤细胞增殖,激活免疫抑制细胞,并支持免疫逸出。然而,尚未报告其在非小细胞肺癌(NSCLC)中的作用。使用定量实时PCR和Western印迹在三种NSClC细胞系(A549,H1299,H1975)和正常肺上皮细胞(BEA-2B)中评估TNFR2。通过免疫组织化学在71个肿瘤组织和25个相邻的正常肺组织中评价TNFR2并相对于临床参数分析。 A549,H1299和H1975细胞中TNFR2的信使RNA和蛋白质水平显着高于BEA-2B细胞(P?<β05),并且通过免疫组织化学在NSCLC组织和相邻的正常肺组织之间显着不同(P?<? 0.0001)。 TNFR2是NSCLC中的独立预后因素。在TNFR2低表达基团和TNFR2高表达组之间的NSCLC患者的NSCLC患者的无病生存(P?= 0.006)和无病的存活(P?= 0.000)显着差异。 TNFR2在人体NSCLC组织和细胞系中表达,与预后不良有关。 TNFR2可以代表NSCLC患者的新辅助指标。 ? 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号